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A Single Center Study of CAPD Catheter Placement Using the
Seldinger Technique
CY Cheung, F Wong, YL Liu, HW Chan, YH Chan, HS Wong, WL Chak,
KS Choi, KF Chau, CS Li
Renal Unit, Department of Medicine, Queen Elizabeth Hospital, Kowloon,
Hong Kong SAR, China.
Background: Percutaneous peritoneal dialysis catheter placement is a rapidly
performed procedure to facilitate rapid initiation of CAPD. We evaluated the
complication and survival rates of CAPD catheters inserted using the Seldinger
technique in our center. Methods: We retrospectively reviewed 70 doubled-
cuff, coiled catheters inserted by nephrologists using the modified Seldinger
technique in 70 consecutive patients between January 2002 and January 2005.
The total experience accumulated was 1,115 patient-months. Results: The mean
age of patients was 54 ( 15 years; 81% were male; 10% had bloody dialysate
(which was mild); 5.7% had subcutaneous leakage; and 1.4% had hernia. There
was no cuff erosion. The main complication was infection. The incidence of
exit site infection was 1 episode/58 patient-months, while the incidence of
peritonitis was 1 episode/80 patient-months. Catheter failure was defined as
catheter malfunction or persistent infection requiring catheter removal. Twenty
patients had their CAPD catheters removed but only 13 were due to catheter
failure. Six were due to catheter malfunction, including catheter tip migration
and obstruction, while seven were due to persistent peritonitis or exit site
infection. Five had their catheters removed after renal transplantation and two
were removed due to accidental damage of the catheters by the patients. The 1-
and 2-year technical survivals were 85% and 80%, respectively. Conclusion:
The complication and survival rates of percutaneous CAPD catheter insertion
were comparable with those reported using surgical techniques. We can state
that percutaneous catheter insertion is a well-tolerated and rapidly performed
alternative procedure.
A Single Center Study on Peritonitis in APD Patients
KH Chu, KS Fung, A Cheuk, KF Yim, HL Tang, W Lee, HWH Chan,
KL Tong
Division of Nephrology, Department of Medicine and Geriatrics,
Princess Margaret Hospital, Lai Chi Kok, Hong Kong SAR, China.
Background: The optimal treatment for peritonitis in APD is not known.
Methods: Retrospective review of hospital and OPD notes. Results: A total of
47 patients were examined: 38.3% were diabetic; 25 patients required helpers.
The duration of therapy ranged from 6 to 97 months. The total therapy time
was 1,695 patient-months. There were 32 episodes of peritonitis reported. The
peritonitis rate was 1 in 53 patient-months. The mean time to first peritonitis
was 21.9 months. The causative organisms were: Gram-positive bacteria,
37.5%; Gram-negative bacteria, 37.5%; culture negative, 12.5%; TB, 6.25%;
and mixed organisms, 6.25%. The breakdown of the bacterial cultures were:
Streptococcus spp, 6/32; MRSA, 4/32; Klebsiella spp, 4/32; Pseudomonas
aeruginosa , 3/32; Escherichia  coli, 2/32; Acinetobacter  spp, 2/32;
Staphylococcus aureus, 1/32; and Enterococci, 1/32. Four patients died during
the same peritonitis episodes: two were related to TB peritonitis; the third died
of AMI; the fourth patient had PD catheter removal and died after prolonged
hospital stay. Twenty-four episodes (85.7%) responded to antibiotics: 22 patients
were treated with in-hospital CAPD followed by antibiotics in APD day-dwell;
one was prescribed outpatient antibiotics in day-dwell at the start; and the last
patient was continued on CAPD until completion of antibiotics. Three of four
catheter removal cases had successful catheter reinsertion. The relative risks
for peritonitis were 2.35, 1.41 and 1.34 for helper status, NIPD and DM
respectively. Conclusion: A regimen of CAPD followed by day-dwell
antibiotics was successful in 85.7% of APD peritonitis. DM, requirement for a
helper, and NIPD were risk factors for the development of peritonitis.
Sleep Apnea in Patients Undergoing Nocturnal Peritoneal Dialysis (NPD)
SCW Tang1,2, WS Leung2, V Chan2, CM Chu2, B Lam1, WO Lam2, YW Ho2,
TM Chan1, MSM Ip1, KN Lai1
1Department of Medicine, Queen Mary Hospital, Pokfulam; 2Department of
Medicine and Geriatrics, United Christian Hospital, Kwun Tong, Hong Kong
SAR, China.
Background: Sleep apnea is prevalent among dialysis patients. Nocturnal
hemodialysis has been shown to improve sleep apnea in patients receiving
conventional hemodialysis. Whether NPD is also effective in correcting sleep
apnea in patients receiving CAPD remains unknown. Methods: We performed
overnight polysomnography in 38 stable NPD and CAPD patients in a sleep
laboratory. NPD patients (n = 19) received a total of 8–10 L of overnight PD
fluid exchanges everyday using an automated cycler, while CAPD patients
(n = 19) underwent 3–4 daily exchanges of 2-L PD fluid. Polysomnographic
findings were scored manually by two independent experts in sleep study who
were blinded to the mode of dialysis. Results: The two groups were matched
for age (mean ( SD for NPD group = 61.4 ( 16.8 years; for CAPD group =
60.2 ( 16.7 years), gender (% male = 47% vs 53%), underlying renal disease
and comorbidities, duration on dialysis (27.8 ( 36.2 months vs 23 ( 14.4
months), body mass index (22.3 ( 3.1 vs 23.9 ( 4.3 kg/m2), and weekly
KT/Vurea (2.4 ( 0.6 vs 2.3 ( 0.4). The prevalence of sleep apnea, defined as an
apnea-hypopnea index (AHI, or total number of episodes of apnea and hypopnea
per hour of sleep) higher than 15, was 58% for NPD patients and 95% for
CAPD patients (p = 0.008). The mean ( SD AHI was 31.6 ( 25.6 versus 50.9 (
26.4 (p = 0.025), while the minimum oxygen saturation was 84.1 ( 8.4% versus
71.0 ( 17.7% (p = 0.008). The frequency of arousal during sleep, periodic leg
movement, and biochemical parameters (serum urea, creatinine, bicarbonate,
and albumin levels) were not significantly different between the two groups.
Conclusion: NPD may have a therapeutic edge over CAPD in sleep apnea
associated with renal failure, which can be validated in further cross-over studies.
PRISMARS as Support for Liver and Multi-organ Failure
CM Chan, RYH Yu, WM Hui, KY Ng, YI Chow, and staff at the
Intensive Care Unit, Hong Kong Sanatorium and Hospital, Central, Hong
Kong SAR, China.
Background: The MARS system was first described in 1993 as a non-biological
system for liver support. PRISMARS is the coupling of such an albumin
absorbent circuit with a continuous hemodiafiltration machine for patients who
cannot tolerate intermittent hemodialysis or who require multi-organ support
therapy in the intensive care unit. PRISMARS was first introduced to Hong
Kong in September 2003. From 1 September 2003 to 15 November 2004, eight
patients (male:female, 6:2) received 47 PRISMARS treatments at the Hong
Kong Sanatorium and Hospital. Two patients had multi-organ failure, three
had primary and two had secondary CA liver, one patient had fulminant hepatitis
(FHF) due to hepatitis E. Treatment protocol: Multi-lumen hemocatheter as
vascular access; 8-hour session at BFR 150 mL/min and UFR 50–150 mL/hr.
Hemosol-Bo solution as replacement fluid at 600–1,000 mL/hr given before
hemofilter; Enoxaparin Na 20 mg at start and 10 mg at 4 hour iv for anti-
coagulation. Results: No mortality or complications were directly related to
PRISMARS therapy. Thirty-day survival was 25%. Total serum bilirubin was
reduced by 20% (425.6 vs 338.4 +mol/L, p = 0.0262). Direct bilirubin was
reduced by 33.4% (330.2 vs 219.8 +mol/L, p = 0.00216). The ammonia level
was reduced by 23.3% (63.2 vs 48.5 +mol/L, p = 0.082). Hemoglobin level
dropped insignificantly from 9.65 to 9.25 g/dL (p = 0.2). Platelet count dropped
insignificantly from 51.9 to 47.5 = 106 (p = 0.55). Mean arterial blood pressure
improved from 60.98 to 66.5 mmHg (p = 0.0177) during PRISMARS treatment.
Conclusion: PRISMARS offers effective, well-tolerated support to multi-organ
failure patients, with a significant reduction in bilirubin levels and improvements
in the hemodynamic and fluid status of critically ill patients. However, its impact
on patient survival remains to be further evaluated.
